ALASPAN TABLET
Out of Stock
Alaspan 10mg Tablet by Bayer Pharmaceuticals is a second-generation, non-sedating oral antihistamine formulated to provide targeted relief from histamine-mediated allergic reactions in companion animals. It addresses a broad spectrum of allergy presentations, including seasonal environmental allergies, allergic skin disease, insect bite and sting reactions, urticaria (hives), and mild to moderate allergic rhinitis, by selectively blocking the peripheral histamine H1 receptor without the marked central nervous system sedation associated with older, first-generation antihistamines. Used under veterinary guidance in dogs and, to a lesser extent, cats, Alaspan 10mg offers a low-sedation, once-daily antihistamine option that can form part of a broader allergy management protocol for your companion animal. Animeal is proud to offer Alaspan 10mg Tablet as part of its curated range of veterinary-applicable pharmaceutical solutions, supporting informed, compassionate allergy care for your canine or feline companion.
Ingredients:
Loratadine (Loratadinum), 10mg per tablet: Loratadine is a second-generation, long-acting tricyclic antihistamine of the piperidine class that exerts its therapeutic effect by competitively and selectively antagonising peripheral histamine H1 receptors. Unlike first-generation antihistamines such as diphenhydramine, loratadine has a low affinity for crossing the blood-brain barrier due to its lipophobic molecular structure and P-glycoprotein-mediated efflux at the blood-brain barrier, which significantly reduces central nervous system penetration and the sedation and anticholinergic effects associated with older agents. At the cellular level, loratadine binds to H1 receptors on mast cells, basophils, vascular endothelium, and sensory nerve endings, preventing histamine from initiating the downstream signalling cascade that produces vasodilation, increased capillary permeability, tissue oedema, pruritus, and smooth muscle contraction. By occupying the H1 receptor before or during histamine release, loratadine intercepts the early-phase allergic response and attenuates the severity of the inflammatory chain, reducing the clinical manifestations of allergic reactions including itching, erythema, urticaria, sneezing, and ocular and nasal discharge. Its extended plasma half-life, along with that of its active metabolite descarboethoxyloratadine, supports sustained H1 receptor occupancy across a once-daily dosing interval, making it particularly effective as a long-term preventive agent rather than purely an acute rescue medication.
